Muscarinic‐3‐receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial
- 14 April 2022
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 41 (5) , 1139-1148
Abstract
Aim: The aim of this study is to evaluate safety and efficacy of ASP8302, a novel positive allosteric modulator for the muscarinic M3 receptor (M3‐PAM), in patients with underactive bladder (UAB).Methods: A randomized, double‐blind, placebo‐controlled multicenter study was performed in adult male/female subjects with UAB, defined as incomplete bladder emptying (postvoid residual volume [PVR] > 100 ml) without significant bladder outlet obstruction and/or overactive bladder. Subjects were randomized (1:1) to receive 4‐week oral once‐daily administration of 100 mg ASP8302 or matching placebo. Primary endpoint was a change from baseline in PVR measured by catheterization after standardized bladder filling (PVRC2). Other endpoints included PVR and bladder voiding efficiency (BVE) measured in various ways, uroflowmetry, bladder diary, and questionnaires. Pressure‐flow studies were performed in a subgroup.Results: One hundred and thirty‐five patients were randomized (ASP8302 group: 65 patients, placebo group: 70 patients). The median change in PVRC2 was −40.0 ml (ASP8302) versus −35.0 ml (placebo) and the difference between groups was −5.0 ml (p = 0.960). In males, functional and symptomatic outcomes improved, for example, maximum urine flow rate (Qmax) and detrusor pressure at Qmax (Pdet.Qmax) increased (mean difference in change ASP8302 vs. placebo: 3.8 ml/s, p = 0.031 and 12.7 cm H2O, p = 0.034, respectively). Urinary incontinence episodes/24 h decreased in males with preexisting incontinence (mean difference: −0.35; p = 0.028). The incidence of adverse events was similar between study groups (ASP8302: 33.3%, placebo: 31.4%). In the included subjects, both baseline urine flow and bladder voiding pressure was low. Compared with PVR, simultaneous BVE measurements were more consistent between various methods (spontaneous vs. standardized bladder filling, catheterization vs. ultrasound [US]).Conclusions: ASP8302 was safe and well tolerated in patients with UAB identified by nonurodynamic clinical criteria, but it did not show efficacy in the primary endpoint. However, in males it showed improvement of symptoms and functional parameters. BVE (using US) is a more optimal outcome measure than PVR in UAB.Keywords
This publication has 24 references indexed in Scilit:
- Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From a Large Group of Patients Undergoing Pressure Flow StudiesEuropean Urology, 2016
- Unravelling detrusor underactivity: Development of a bladder outlet resistance—Bladder contractility nomogram for adult male patients with lower urinary tract symptomsNeurourology and Urodynamics, 2015
- Measurement of post‐void residual urineNeurourology and Urodynamics, 2014
- The many faces of impaired bladder emptyingCurrent Opinion in Urology, 2014
- Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and DiagnosisEuropean Urology, 2014
- Functional consequences of chronic bladder ischemiaNeurourology and Urodynamics, 2013
- The Relation between Postvoid Residual and Occurrence of Urinary Tract Infection after Stroke in Rehabilitation UnitAnnals of Rehabilitation Medicine, 2012
- A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: Data from a randomized controlled trial of surgery for women with stress incontinenceAmerican Journal of Obstetrics and Gynecology, 2004
- SCORING THE SHORT FORM ICSmaleSF QUESTIONNAIREJournal of Urology, 2000
- The Effects of Norephedrine and Bethanechol on the Human Urethral Closure Pressure ProfileScandinavian Journal of Urology and Nephrology, 1978